ANAB
ANAPTYSBIO, INC
$51.36
+1.97%
$1.5B
No data for this timeframe.
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders8 funds
Inst. Value$159.5M
Inst. Activity1 buys / 3 sells
Insider Activity0B / 3S
Insider Net $-$1.3M
Reddit Sentiment50° Neutral
SEC Reports12
Press Releases3
Recent Activity
Dec 12, 2026
fda_pdufa
PDUFA: ANAB — imsidolimab in generalized pustular psoriasis (GPP) — 2026-12-12
FDA target action date 2026-12-12 for ANAB (ANAPTYSBIO, INC). Drug: imsidolimab. Indication: general
Jun 8, 2026
SEC
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 21,987 shares of common stock, with a
144 — Impact 5/10
Jun 5, 2026
SEC
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 22,491 shares of co
144 — Impact 5/10
Jun 5, 2026
SEC
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 20,000 common share
144 — Impact 5/10
May 11, 2026
Insider
Hughes Owen sold 11,250 shares
Director @ $0.00 ($0.00)
May 11, 2026
Insider
Murphy Christopher M. sold 25,765 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 20, 2026
Insider
Faga Daniel sold 11,000 shares
President, CEO @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — TRIM
1,034,562 shares ($50.2M)
Price Targets
$84.45
+63.6% upside
Strong Buy
Current $51.63
Low $66.00
Median $78.00
High $140.00
11 analysts
$66.00
$140.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 13, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 4, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.39 ▲ +285.4% | $-0.08 — $1.03 | 129% YoY | 4 |
| Next Q | $0.47 ▲ +342.9% | $-0.08 — $1.29 | -10% YoY | 5 |
| Current FY | $0.37 ▲ +335.5% | $-1.93 — $2.49 | 180% YoY | 4 |
| Next FY | $5.83 ▲ +389.8% | $4.50 — $8.77 | 1479% YoY | 4 |
Latest Reports
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 21,987 shares of common stock, with a
Jun 8, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 22,491 shares of co
Jun 5, 2026
BULLISH
Press
7/10
AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Cour
Apr 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $74.9M | — |
| MORGAN STANLEY | $50.2M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $12.4M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $9.6M | ADD |
| BANK OF AMERICA CORP | $6.3M | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | Hughes Owen | A | $0.00 |
| May 11, 2026 | Murphy Christopher | A | $0.00 |
| Apr 20, 2026 | Faga Daniel | D | $0.00 |
| Apr 20, 2026 | Faga Daniel | D | $0.00 |
| Apr 20, 2026 | Faga Daniel | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $159.5M total value (3,290,276 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net selling activity: 3 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,544,037 | $74.9M | 46.9% | — |
| 2 | MORGAN STANLEY | 1,034,562 | $50.2M | 31.4% | TRIM -33.5% |
| 3 | TWO SIGMA INVESTMENTS, LP | 256,635 | $12.4M | 7.8% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 198,660 | $9.6M | 6.0% | ADD +31.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 130,767 | $6.3M | 4.0% | NEAR_EXIT -88.2% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 76,300 | $3.7M | 2.3% | TRIM -38.1% |
| 7 | FMR LLC | 27,108 | $1.3M | 0.8% | TRIM -49.0% |
| 8 | WELLS FARGO & COMPANY/MN | 22,207 | $1.1M | 0.7% | ADD +61.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 1,556,258 | 1,034,562 | -33.5% | $50.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 123,300 | 76,300 | -38.1% | $3.7M | 2025-Q4 |
| FMR LLC | TRIM | 53,162 | 27,108 | -49.0% | $1.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 13,743 | 22,207 | +61.6% | $1.1M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 157,135 | 206,441 | +31.4% | $6.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 1,076,799 | 127,241 | -88.2% | $3.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 263,086 | 123,300 | -53.1% | $3.8M | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 1,272,499 | 75,262 | -94.1% | $2.3M | 2025-Q3 |
| FMR LLC | TRIM | 72,119 | 53,162 | -26.3% | $1.6M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 33,328 | 13,743 | -58.8% | $420.8K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 504,636 | 1,869,840 | +270.5% | $41.5M | 2025-Q2 |
| UBS Group AG | DOUBLED | 490,273 | 1,272,499 | +159.5% | $28.2M | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 1,905,154 | 72,119 | -96.2% | $1.6M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 11,377 | 33,328 | +192.9% | $739.9K | 2025-Q2 |
| FMR LLC | TRIM | 3,030,236 | 1,905,154 | -37.1% | $35.4M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 215,917 | 504,636 | +133.7% | $9.4M | 2025-Q1 |
| UBS Group AG | DOUBLED | 36,606 | 490,273 | +1239.3% | $9.1M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 193,200 | 338,700 | +75.3% | $6.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 273,245 | 398,327 | +45.8% | $5.3M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 27,097 | 11,120 | -59.0% | $147.2K | 2024-Q4 |
| MORGAN STANLEY | ADD | 91,768 | 177,382 | +93.3% | $5.9M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 160,321 | — | $5.4M | 2024-Q3 |
7 unique insiders with 3 transactions. Net insider value: -$1.3M ($0.00 bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Hughes Owen | Director | A | 11,250 | $0.00 | $0.00 |
| May 11, 2026 | Murphy Christopher M. | Chief Financial Officer | A | 25,765 | $0.00 | $0.00 |
| Apr 20, 2026 | Faga Daniel | President, CEO | D | 11,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Faga Daniel | President, CEO | D | 11,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Faga Daniel | President, CEO | A | 11,000 | $0.00 | $0.00 |
| Apr 20, 2026 | RENTON HOLLINGS | Director | D | 15,000 | $0.00 | $0.00 |
| Apr 20, 2026 | RENTON HOLLINGS | Director | A | 15,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Schmid John P. | Director | D | 15,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Schmid John P. | Director | A | 15,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Orwin John A | Director | D | 3,311 | $0.00 | $0.00 |
| Apr 20, 2026 | Orwin John A | Director | A | 3,311 | $0.00 | $0.00 |
| Mar 30, 2026 | Schmid John P. | Director | SELL | 12,596 | $55.71 | $701.7K |
| Mar 27, 2026 | Faga Daniel | President, CEO | SELL | 510 | $56.61 | $28.9K |
| Mar 25, 2026 | Faga Daniel | President, CEO | A | 34,300 | $0.00 | $0.00 |
| Feb 11, 2026 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | M | 10,000 | $0.00 | $0.00 |
| Feb 11, 2026 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | SELL | 10,000 | $54.00 | $540.0K |
| Feb 11, 2026 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | M | 10,000 | $29.70 | $297.0K |
12 SEC filing reports analyzed. Sentiment: 1 bullish, 8 bearish, 0 mixed, 3 neutral. Avg impact: 4.8/10.
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 21,987 shares of
Jun 8, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell
Jun 5, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell
Jun 5, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 10,000 shares of
Jun 5, 2026
BEARISH
144
5/10
CEO Dennis Mulroy filed a Form 144 to sell 20,000 shares (~$1.0M at filing) via a stock option exerc
Jun 3, 2026
BEARISH
144
5/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 1, 2026, indicating intent to sell
Jun 1, 2026
NEUTRAL
8-K
2/10
AnaptysBio filed an 8-K under Item 7.01 to disclose that it has filed Form 8937 with the IRS regardi
May 29, 2026
NEUTRAL
144
3/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 28, 2026, indicating intent to sell
May 28, 2026
BEARISH
144
6/10
CEO Dennis Mulroy filed a Form 144 notice to sell 10,000 shares of AnaptysBio common stock, valued a
May 27, 2026
NEUTRAL
144
3/10
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 15, 2026, indicating intent to sell
May 15, 2026
BULLISH
PRESS-RELEASE
7/10
AnaptysBio reported Q4 2025 EPS of $1.58, a 268% beat vs consensus of -$0.94, indicating strong oper
May 4, 2026
BEARISH
CLUSTER
7/10
Two corporate insiders at AnaptysBio sold shares worth $731K within a 7-day window, including CEO Da
Apr 2, 2026
BULLISH
7/10
AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the De
Apr 24, 2026
MIXED
7/10
AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured
Mar 27, 2026
BULLISH
8/10
AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli roy
Mar 3, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$84.45 mean target
+63.6% upside
Strong Buy (1.27)
$66.00 Low
$140.00 High
| Metric | Value |
|---|---|
| Current Price | $51.63 |
| Target Low | $66.00 |
| Target Mean | $84.45 |
| Target Median | $78.00 |
| Target High | $140.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.39 | $-0.08 | $1.03 | 129.1% | +285.4% | 0↑ 3↓ | $0.0B | -15.5% | 4 |
| Next Q 2026-09-30 |
$0.47 | $-0.08 | $1.29 | -10.1% | +342.9% | 0↑ 3↓ | $0.0B | -65.9% | 5 |
| Current FY 2026-12-31 |
$0.37 | $-1.93 | $2.49 | 180.2% | +335.5% | 0↑ 3↓ | $0.1B | -53.2% | 4 |
| Next FY 2027-12-31 |
$5.83 | $4.50 | $8.77 | 1479.3% | +389.8% | 1↑ 2↓ | $0.2B | 38.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.389 | |
| 7d ago | $0.427 | -0.038 |
| 30d ago | $-0.210 | +0.599 |
| 60d ago | $-0.880 | +1.270 |
| 90d ago | $-1.036 | +1.426 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 13, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 4, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 17, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Mar 5, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 7 | 9 | 3 | 0 | 0 | 84% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Dec 12, 2026
fda_pdufa
PDUFA: ANAB — imsidolimab in generalized pustular psoriasis (GPP) — 2026-12-12
FDA target action date 2026-12-12 for ANAB (ANAPTYSBIO, INC). Drug: imsidolimab. Indication: generalized pustular psoriasis (GPP). FDA accepted the BL
May 12, 2026
earnings
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
<p>SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for <em>J
May 11, 2026
other
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
<p align="left">SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborati
May 7, 2026
earnings_calendar
ANAB Q1 2026 Earnings After Market Close — 2026-05-07
May 7, 2026
short_volume
Short Volume: ANAB — 55.5% short (0.3M / 0.5M)
Short: 286,023 | Exempt: 0 | TRF Vol: 515,581 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
<p align="left">SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborati
May 4, 2026
earnings_calendar
ANAB Q1 2026 Earnings After Market Close — 2026-05-04
Apr 24, 2026
contract
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
<p align="left">SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collabora
Apr 20, 2026
other
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
<p>SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of it
Apr 1, 2026
short_interest
FTD: ANAB — 21,487 shares ($1.2M) failed to deliver
Settlement: 20260401, Price: $55.46, FTD Value: $1,191,669.02, ANAPTYSBIO INC COM STK (DE)
Mar 27, 2026
other
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
<p>SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previo
Mar 27, 2026
offering
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
<p>SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeu
Mar 27, 2026
buyback
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
<p align="left">SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has author
Mar 9, 2026
earnings_calendar
ANAB Q4 2025 Earnings After Market Close — 2026-03-09
Mar 3, 2026
earnings
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
<p>SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innov